Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI.

Abstract

Two novel stem cell factor (SCF) dependent human mast cell lines, designated LAD 1 and 2, were established from bone marrow aspirates from a patient with mast cell sarcoma/leukemia. LAD 1 and 2 cells have the ultrastructural features of human mast cells, and express FcepsilonRI, CD4, 9, 13, 14, 22, 31, 32, 45, 64, 71, 103, 117, 132, CXCR4 (CD184), CCR5 (CD195); and intracytoplasmic histamine, tryptase and chymase. LAD 1 and 2 do not exhibit activating mutations at codon 816 of c-kit. Both LAD 1 and 2 release beta-hexosaminidase following FcepsilonRI or FcgammaRI aggregation. The availability of these cell lines offers an unparalleled circumstance to examine the biology of human mast cells.

• Authors: Arnold S Kirshenbaum, Cem Akin, Yalin Wu, Menachem Rottem, Julie P Goff, Michael A Beaven, V Koneti Rao, Dean D Metcalfe
• Journal: Leukemia research (Leuk Res) Vol. 27 Issue 8 Pg. 677-82 (Aug 2003) ISSN: 0145-2126 [Print] England
• PMID: 12801524 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Receptors, IgE
• Receptors, IgG
• Stem Cell Factor

Topics

• Adult
• Bone Marrow Cells (pathology)
• Cell Division
• Cell Line
• Dimerization
• Humans
• Immunophenotyping
• Karyotyping
• Leukemia, Mast-Cell (enzymology, genetics, pathology)
• Male
• Mast Cells (enzymology, pathology)
• Mast-Cell Sarcoma (enzymology, genetics, pathology)
• Mutation
• Receptors, IgE (metabolism)
• Receptors, IgG (metabolism)
• Stem Cell Factor (pharmacology)